Full Press Release Details
Lexaria Welcomes Canada s Proposed Cannabis
Kelowna, BC / April 18, 2017 / Lexaria Bioscience Corp
(OTCQB:LXRP) (CSE:LXX) (the Company , Lexaria ) welcomes the newly proposed
Canadian legislation designed to allow for adult legal access to Cannabis (the
Cannabis Act ). In line with the Cannabis Act s objective to protect public
health and public safety, powerful demographic and lifestyle forces are
trending away from both the harmful effects related to inhalational dosing
(smoking/vaping) and from edibles with high sugar & fat content.
The Cannabis Act provides the opportunity for Canada to craft
the safest and most responsible cannabis production and consumption framework in
the world, especially with respect to consistent and reliable dosing formats
that technology such as Lexaria s enables in modern edible formats. The Cannabis
Act prohibits second hand smoke and second hand vapours from inhaled cannabis
use, consistent with existing federal legislation that prohibits second hand
cigarette smoke. It is also in everyone s best interest to support the consumer
shift away from the high sugar, high fat, inconsistent and unpredictable
effectiveness and onset-times associated with edible product formats endemic in
other adult-use cannabis markets.
Lexaria s patented technology currently subject to
collaborative examination together with Canada s National Research Council is
strongly supportive of macro trends by embracing edible cannabis formats with
zero added sugar, and lower micro-dosage unit sizes. Micro dosing of 10mg and
even as little as 5mg of THC is rapidly gaining popularity in other legal
cannabis jurisdictions that mandate micro dosing edible formats as a more
responsible way of consuming cannabis, without creating issues of second hand
smoke or second hand vapour for non-consumers. Micro dosing tends to lead to
lower overall levels of consumption with reduced likelihood of overconsumption.
Modern technology allows for safer, more consistent and less
obtrusive methods of cannabis use than ever before, says Chris Bunka, CEO of
Lexaria. We have a once in a lifetime opportunity to support consumer health
trends in the cannabis world through advanced delivery techniques unlike
anything available even five years ago. I hope to see Canada lead the world in
embracing public health in the cannabis sector. While utilizing Lexaria s
technology, both in vitro and human biomarker studies point to
significantly higher cannabinoid absorption and quicker & and more
consistent onset of effects than can be achieved with conventional edible
preparations. Further consumer focus studies conducted by Lexaria licensees have
reported a more pleasurable, faster acting and predictable experience.
Through a patented process that combines cannabinoids with
natural delivery enhancers at a molecular level, Lexaria s technology is
believed to alter the absorption pathway of cannabinoids within the human body
(designed to bypass first-pass liver filtration when desired for more rapid
onset of effectiveness). More efficient and effective absorption of cannabinoids
has been shown, while simultaneously masking and even eliminating inherent
strong flavours and odors typical of cannabis extracts, avoiding the need for
added sugar and fat. Lexaria s technology was conceived to allow for the
creation of edible product formats that mirror as closely as possible the
potency and onset of effectiveness associated with inhalational dosing without
its unwanted effects. Lexaria is thrilled to have the opportunity to lead
advancements in bio-availability and speed & predictability of onset for
health-conscious consumers.
Lexaria Bioscience Corp. is a food
biosciences company with a proprietary technology for improved delivery of
bioactive compounds. The Company s lipophilic enhancement technology has been
shown to enhance the bioavailability of orally ingested cannabinoids, while also
masking taste. This technology promotes healthy ingestion methods, lower overall
dosing and higher effectiveness in active molecule delivery. The Company s
technology is patent-protected for cannabidiol (CBD) and all other
non-psychoactive cannabinoids, and patent-pending for Tetrahydrocannabinol
(THC), other psychoactive cannabinoids, non-steroidal anti-inflammatory drugs
(NSAIDs), nicotine and other molecules.
FOR FURTHER INFORMATION PLEASE CONTACT:
FORWARD-LOOKING STATEMENTS
This release includes
forward-looking statements. Statements which are not historical facts are
forward-looking statements. The Company makes forward-looking public statements
concerning its expected future financial position, results of operations, cash
flows, financing plans, business strategy, products and services, competitive
positions, growth opportunities, plans and objectives of management for future
operations, including statements that include words such as "anticipate," "if,"
"believe," "plan," "estimate," "expect," "intend," "may," "could," "should,"
"will," and other similar expressions are forward-looking statements. Such
forward-looking statements are estimates reflecting the Company's best judgment
based upon current information and involve a number of risks and uncertainties,
and there can be no assurance that other factors will not affect the accuracy of
such forward-looking statements. Factors which could cause actual results to
differ materially from those estimated by the Company include, but are not
limited to, government regulation, managing and maintaining growth, the effect
of adverse publicity, litigation, competition, the patent application and
approval process and other factors which may be identified from time to time in
the Company's public announcements and filings. There is no assurance that
existing capital is sufficient for the Company's needs or that it will be able
to raise additional capital. There is no assurance that Lexaria will
successfully complete any other contemplated or existing technology license
agreements, nor that Lexaria s technology will deliver any improvement in taste
or bioavailability with any reliability nor across any product category. There
is no assurance that any planned corporate activity, business venture, or
initiative will be pursued, or if pursued, will be successful. There is no
assurance that any hemp oil or cannabinoid-based product will promote, assist,
or maintain any beneficial human health conditions whatsoever, nor that any
patent application in the USA or any other nation or under any treaty will
result in the award of an actual patent; nor that an award of any actual patent
will protect against challenges from unknown third parties. There is no
assurance that any of Lexaria s postulated uses, benefits, or advantages for the
patent-pending technology will in fact be realized in any manner or in any part.
No statement herein has been evaluated by the Food and Drug Administration
(FDA)or by Health Canada. Lexaria products are not intended to diagnose, treat,
cure or prevent any disease.
The CSE has not reviewed and does not accept responsibility